Published in Pediatrics on September 01, 1998
Humanized monoclonal antibody for prevention of respiratory syncytial virus infection. Pediatrics (1998) 43.87
Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science (2013) 3.90
Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev (2010) 3.31
Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science (2013) 2.95
Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol (2011) 2.53
Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res (2011) 2.51
Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev (2000) 2.38
Trends in bronchiolitis hospitalizations in the United States, 2000-2009. Pediatrics (2013) 2.14
Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev (2000) 2.07
Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev (2011) 2.04
Structural basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct Mol Biol (2010) 1.89
Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A (2012) 1.80
Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature (2013) 1.73
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine (2007) 1.68
Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Sci Transl Med (2015) 1.67
Animal pneumoviruses: molecular genetics and pathogenesis. Clin Microbiol Rev (2004) 1.67
Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. Am J Respir Crit Care Med (2015) 1.65
Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env. Nat Struct Mol Biol (2015) 1.64
Importance of respiratory viruses in acute otitis media. Clin Microbiol Rev (2003) 1.60
Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis (2013) 1.60
Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. J Virol (2001) 1.58
Strategic priorities for respiratory syncytial virus (RSV) vaccine development. Vaccine (2013) 1.56
Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A (2013) 1.51
Evidence for a causal relationship between respiratory syncytial virus infection and asthma. Expert Rev Anti Infect Ther (2011) 1.51
Comments on palivizumab (Synagis) Pediatrics (1999) 1.45
Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J (2011) 1.45
The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virus. Epidemiol Infect (2007) 1.43
Reduced-Dose Schedule of Prophylaxis Based on Local Data Provides Near-Optimal Protection Against Respiratory Syncytial Virus. Clin Infect Dis (2015) 1.42
Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. J Mol Biol (2011) 1.39
Agents that increase AAM differentiation blunt RSV-mediated lung pathology. J Leukoc Biol (2014) 1.39
Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J Virol (2010) 1.38
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults. Clin Exp Immunol (2015) 1.35
The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya. PLoS One (2009) 1.35
RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother (2007) 1.34
Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother (2005) 1.32
Human genetic factors and respiratory syncytial virus disease severity. Clin Microbiol Rev (2008) 1.30
Whole genome characterization of non-tissue culture adapted HRSV strains in severely infected children. Virol J (2011) 1.29
Epidemiology of hospitalization for acute bronchiolitis in children: differences between RSV and non-RSV bronchiolitis. Eur J Clin Microbiol Infect Dis (2012) 1.25
Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia. Infect Immun (2002) 1.24
A systemic neutrophil response precedes robust CD8(+) T-cell activation during natural respiratory syncytial virus infection in infants. J Virol (2009) 1.24
Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein. PLoS Pathog (2015) 1.23
Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Rev Vaccines (2008) 1.23
Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis. Pediatr Infect Dis J (2014) 1.21
Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model. Antimicrob Agents Chemother (2004) 1.21
Neutralization of human respiratory syncytial virus infectivity by antibodies and low-molecular-weight compounds targeted against the fusion glycoprotein. J Virol (2010) 1.21
New insights for development of a safe and protective RSV vaccine. Hum Vaccin (2010) 1.18
Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol (2013) 1.15
Neonatal innate immunity to infectious agents. Infect Immun (2006) 1.11
Role of respiratory syncytial virus in acute otitis media: implications for vaccine development. Vaccine (2006) 1.10
Monoclonal antibodies and toxins--a perspective on function and isotype. Toxins (Basel) (2012) 1.09
Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo. J Virol (2006) 1.09
Epidemiologic, experimental, and clinical links between respiratory syncytial virus infection and asthma. Clin Microbiol Rev (2008) 1.09
Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV). Ital J Pediatr (2015) 1.08
Altered pathogenesis of severe pneumovirus infection in response to combined antiviral and specific immunomodulatory agents. J Virol (2003) 1.08
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design. Nat Struct Mol Biol (2015) 1.07
Maternal immunization. Clin Infect Dis (2014) 1.07
Mucosal inoculation with an attenuated mouse pneumovirus strain protects against virulent challenge in wild type and interferon-gamma receptor deficient mice. Vaccine (2006) 1.06
Respiratory viruses other than influenza virus: impact and therapeutic advances. Clin Microbiol Rev (2008) 1.05
Prospective validation of a prognostic model for respiratory syncytial virus bronchiolitis in late preterm infants: a multicenter birth cohort study. PLoS One (2013) 1.05
Human PIV-2 recombinant Sendai virus (rSeV) elicits durable immunity and combines with two additional rSeVs to protect against hPIV-1, hPIV-2, hPIV-3, and RSV. Vaccine (2009) 1.05
Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent? Paediatr Child Health (1998) 1.04
Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A. Vaccine (2008) 1.03
Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol (2010) 1.03
Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines. J Virol (1999) 1.03
Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Health (1999) 1.03
An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children. BMC Public Health (2011) 1.03
Chinchilla and murine models of upper respiratory tract infections with respiratory syncytial virus. J Virol (2005) 1.03
Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect Dis (2011) 1.03
Temporal trends in emergency department visits for bronchiolitis in the United States, 2006 to 2010. Pediatr Infect Dis J (2014) 1.03
Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective. Int J Pediatr (2014) 1.02
Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother (2012) 1.02
A retrospective population-based cohort study identifying target areas for prevention of acute lower respiratory infections in children. BMC Public Health (2010) 1.02
A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can Respir J (2011) 1.01
Role of the lipoxygenase pathway in RSV-induced alternatively activated macrophages leading to resolution of lung pathology. Mucosal Immunol (2013) 1.01
Intranasal antibody prophylaxis for protection against viral disease. Clin Microbiol Rev (1999) 1.00
Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients. Semin Respir Crit Care Med (2011) 1.00
A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP Study. Respir Res (2008) 0.99
Sendai virus-based RSV vaccine protects African green monkeys from RSV infection. Vaccine (2011) 0.98
Incidence and risk factors of hospitalization for bronchiolitis in preterm children: a retrospective longitudinal study in Italy. BMC Pediatr (2009) 0.98
Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats. Antimicrob Agents Chemother (2002) 0.98
Respiratory syncytial virus vaccine development. Clin Lab Med (2009) 0.98
Respiratory syncytial virus infection and bronchiolitis. Pediatr Rev (2014) 0.98
B cells and antibodies in the defense against Mycobacterium tuberculosis infection. Immunol Rev (2015) 0.97
Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus. J Virol (2009) 0.97
Prevention of respiratory syncytial virus infection. Paediatr Child Health (2009) 0.97
Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations. Eur J Pediatr (2011) 0.97
Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev (2009) 0.96
Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review. Infect Dis Ther (2014) 0.96
A meta-analysis of the effect of antibody therapy for the prevention of severe respiratory syncytial virus infection. BMC Infect Dis (2009) 0.96
A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles. PLoS One (2013) 0.96
Viral lower respiratory tract infection in infants and young children. BMJ (2003) 0.96
Respiratory syncytial virus is associated with an inflammatory response in lungs and architectural remodeling of lung-draining lymph nodes of newborn lambs. Am J Physiol Lung Cell Mol Physiol (2010) 0.95
HIV monoclonal antibodies: a new opportunity to further reduce mother-to-child HIV transmission. PLoS Med (2014) 0.95
A respiratory syncytial virus (RSV) anti-G protein F(ab')2 monoclonal antibody suppresses mucous production and breathing effort in RSV rA2-line19F-infected BALB/c mice. J Virol (2013) 0.95
Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health (2015) 0.95
Compliance with RSV prophylaxis: Global physicians' perspectives. Patient Prefer Adherence (2009) 0.95
Social, economic, and health impact of the respiratory syncytial virus: a systematic search. BMC Infect Dis (2014) 0.94
Humanized monoclonal antibody for prevention of respiratory syncytial virus infection. Pediatrics (1998) 43.87